135 results on '"Lombardo, Mary-Jane"'
Search Results
2. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
3. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection
4. Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
5. Reply to Lagier et al
6. The PapC Usher Forms an Oligomeric Channel: Implications for Pilus Biogenesis across the Outer Membrane
7. Manufacturing Process of Investigational Microbiome Therapeutic, SER-109, Reduces Risk of Bacterial Pathogen Transmission
8. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection
9. Stressful Lifestyle-Associated Mutation in Microorganisms
10. A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation
11. Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
12. Assessment of a rationally-designed experimental microbial consortium to reduce systemic inflammation in a murine model of chemotherapy-induced mucositis.
13. A phase 1b study to evaluate safety, tolerability, pharmacokinetics, and efficacy of SER-155 in adults undergoing hematopoietic stem cell transplantation to reduce the risk of infection and graft versus host disease (NCT04995653).
14. Candidate phylum TM6 genome recovered from a hospital sink biofilm provides genomic insights into this uncultivated phylum
15. Identity and Function of a Large Gene Network Underlying Mutagenic Repair of DNA Breaks
16. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
17. An in vivo Expression Technology Screen for Vibrio cholerae Genes Expressed in Human Volunteers
18. 1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool
19. 130. Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
20. LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics
21. Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
22. Prospective longitudinal evaluation of microbiome diversity in patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
23. Fr572 24-WEEK EFFICACY AND SAFETY DATA FROM ECOSPOR-III, A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
24. General stress response regulator RpoS in adaptive mutation and amplification in Escherichia coli
25. Identity and Function of a Large Gene Network Underlying Mutagenic Repair of DNA Breaks
26. Hypermutation in stationary-phaseE. coli: tales from thelac operon
27. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
28. radC102 of Escherichia coli is an allele of recG
29. The σE stress response is required for stress-induced mutation and amplification in Escherichia coli
30. Mismatch repair in Escherichia coli cells lacking single-strand exonucleases ExoI, ExoVII and RecJ
31. Regulation of Salmonella typhimurium pepT gene by cyclic AMP receptor protein (CRP) and FNR acting at a hybrid CRP-FNR site
32. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
33. xni-deficient Escherichia coli are proficient for recombination and multiple pathways of repair
34. Mechanisms of Genome-Wide Hypermutation in Stationary Phasea
35. Recombination-dependent mutation in Escherichia coli occurs in stationary phase
36. Reply to Lagier et al
37. Stationary-phase mutation in the bacterial chromosome: Recombination protein and DNA polymerase IV dependence
38. A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
39. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection
40. Atypical Role for PhoU in Mutagenic Break Repair under Stress in Escherichia coli
41. Vancomycin-Resistant Enterococcal iters Diminish Among Patients With Recurrent Clostridium difficile Infection After Administration of SER-109, A Novel Microbiome Agent
42. Critical Microbiological View of SER-109.
43. Genome of the pathogen Porphyromonas gingivalis recovered from a biofilm in a hospital sink using a high-throughput single-cell genomics platform
44. Physical mapping of the Escherichia coli pepT and potABCD genes
45. Genomic insights to SAR86, an abundant and uncultivated marine bacterial lineage
46. Efficient de novo assembly of single-cell bacterial genomes from short-read data sets
47. Going Deeper: Metagenome of a Hadopelagic Microbial Community
48. General Stress Response Regulator RpoS in Adaptive Mutation and Amplification inEscherichia coli
49. The TGV transgenic vectors for single-copy gene expression from the Escherichia coli chromosome
50. SOS Mutator DNA Polymerase IV Functions in Adaptive Mutation and Not Adaptive Amplification
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.